Serum Magnesium Levels Associated with CAP Mortality
|
By LabMedica International staff writers Posted on 07 Jan 2019 |

Image: The Dimension EXL 200 integrated chemistry system (Photo courtesy of Siemens Healthcare).
Community acquired pneumonia (CAP) is a common illness affecting hundreds of millions worldwide, with increasing hospital admissions throughout the years mainly due to the aging population. It is a major cause of mortality and morbidity in all age groups, especially the elderly.
Magnesium deficiency has been associated with a number of clinical manifestations such as arrhythmias, cardiac insufficiency, sudden death, muscle weakness, bronchospasm, tetany, seizures, as well as hypokalemia, hypocalcaemia, hyponatremia, and hypophosphatemia. Hypermagnesemia may cause severe symptomatic hypotension, bradycardia and ECG changes like wide QRS.
Scientists at the Rambam Health Care Campus (Haifa, Israel) and their colleagues retrospectively reviewed between January 1, 2010, and December 31, 2016, the data of 4,708 patients diagnosed with CAP at discharge; 3,851 patients had magnesium levels within 48 hours, and 55% were males and the median age was 72 years old. Participants were analyzed retrospectively in order to identify the risk factors for a primary endpoint of 30-day mortality.
The Charlson’s comorbidity score was calculated based on data collected; laboratory values (first values within 48 hours): Hemoglobin (Hb), White blood cell count (WBC), red blood cell distribution width (RDW), pH, partial pressure of carbon dioxide (pCO2), serum glucose, serum creatinine, sodium, calcium, phosphorus, magnesium, blood urea nitrogen (BUN), and serum albumin. Hematological values were measured using the Advia 120 Hematology Analyzer. Serum glucose, serum creatinine, sodium, calcium, phosphorus, magnesium, blood urea nitrogen (BUN), and serum albumin were measured on admission using Siemens’ Dimension Integrated Chemistry System; PH, bicarbonate, partial pressure of CO2 and lactate were measured using GEM premier 3500.
The team reported that blood urea nitrogen (BUN) > 20 mg/dL, hypoalbuminemia, and abnormal levels of magnesium were all associated with increased risk of 30-day mortality. Normal magnesium levels were associated with the lowest mortality rate (14.7%). Notably, within the normal levels, high normal magnesium levels (2.0 to 2.4 mg/dL) were correlated with higher mortality rates (30.3%) as compared to levels that ranged between 1.35 to 2 mg/dL (12.9%). Hypomagnesemia and hypermagnesemia were both associated with excess of 30-day mortality, 18.4 and 50%, respectively. Normal levels of magnesium levels in their laboratory vary between 1.35 and 2.4 mg/dL.
The authors concluded that hypomagnesemia and hypermagnesemia on admission were associated with an increased rate of 30-day mortality among adult patients hospitalized with CAP. Interestingly, magnesium levels within the upper normal limits were associated with higher mortality. The study was published on December 27, 2018, in the journal BMC Infectious Diseases.
Related Links:
Rambam Health Care Campus
Magnesium deficiency has been associated with a number of clinical manifestations such as arrhythmias, cardiac insufficiency, sudden death, muscle weakness, bronchospasm, tetany, seizures, as well as hypokalemia, hypocalcaemia, hyponatremia, and hypophosphatemia. Hypermagnesemia may cause severe symptomatic hypotension, bradycardia and ECG changes like wide QRS.
Scientists at the Rambam Health Care Campus (Haifa, Israel) and their colleagues retrospectively reviewed between January 1, 2010, and December 31, 2016, the data of 4,708 patients diagnosed with CAP at discharge; 3,851 patients had magnesium levels within 48 hours, and 55% were males and the median age was 72 years old. Participants were analyzed retrospectively in order to identify the risk factors for a primary endpoint of 30-day mortality.
The Charlson’s comorbidity score was calculated based on data collected; laboratory values (first values within 48 hours): Hemoglobin (Hb), White blood cell count (WBC), red blood cell distribution width (RDW), pH, partial pressure of carbon dioxide (pCO2), serum glucose, serum creatinine, sodium, calcium, phosphorus, magnesium, blood urea nitrogen (BUN), and serum albumin. Hematological values were measured using the Advia 120 Hematology Analyzer. Serum glucose, serum creatinine, sodium, calcium, phosphorus, magnesium, blood urea nitrogen (BUN), and serum albumin were measured on admission using Siemens’ Dimension Integrated Chemistry System; PH, bicarbonate, partial pressure of CO2 and lactate were measured using GEM premier 3500.
The team reported that blood urea nitrogen (BUN) > 20 mg/dL, hypoalbuminemia, and abnormal levels of magnesium were all associated with increased risk of 30-day mortality. Normal magnesium levels were associated with the lowest mortality rate (14.7%). Notably, within the normal levels, high normal magnesium levels (2.0 to 2.4 mg/dL) were correlated with higher mortality rates (30.3%) as compared to levels that ranged between 1.35 to 2 mg/dL (12.9%). Hypomagnesemia and hypermagnesemia were both associated with excess of 30-day mortality, 18.4 and 50%, respectively. Normal levels of magnesium levels in their laboratory vary between 1.35 and 2.4 mg/dL.
The authors concluded that hypomagnesemia and hypermagnesemia on admission were associated with an increased rate of 30-day mortality among adult patients hospitalized with CAP. Interestingly, magnesium levels within the upper normal limits were associated with higher mortality. The study was published on December 27, 2018, in the journal BMC Infectious Diseases.
Related Links:
Rambam Health Care Campus
Latest Microbiology News
- Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
- Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
- FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection
- Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
- Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
- Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
- Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- Study Highlights Need for Routine Hepatitis E Testing in Cirrhosis
- High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Channels
Molecular Diagnostics
view channel
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read morePathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more





.jpg)

